NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Preclinical data presented at first AACR virtual special conference on radiation science and medicine showed NBTXR3 combo overcomes anti-PD-1 resistance, promotes strong abscopal effect and long-term anti-cancer memory
    Nanobiotix announces 2020 Q4 and annual revenues
    Nanobiotix announces first patient injected with NBTXR3 in esophageal cancer



    March 22, 2021

    Bio-Europe Spring

    More info
    March 2-3, 2021

    Radiation Science and medicine working group

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation